Free Trial

Enlivex Therapeutics (ENLV) Earnings Date, Estimates & Call Transcripts

Enlivex Therapeutics logo
$1.07 -0.01 (-0.93%)
(As of 11/15/2024 ET)

Enlivex Therapeutics Latest Earnings Summary

Latest Q2 2024
Earnings Date
Aug. 30Estimated
Actual EPS
(Aug. 30)
-$0.16 Beat By $0.06
Consensus EPS
(Aug. 30)
-$0.22

Enlivex Therapeutics released Q2 2024 earnings on August 30, 2024, reporting an EPS of -$0.16, which topped analysts' consensus estimates of -$0.22 by $0.06. With a trailing EPS of -$1.18, Enlivex Therapeutics' earnings are expected to grow next year, from ($0.70) to ($0.58) per share.

Get Enlivex Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ENLV Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ENLV Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Enlivex Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.21-$0.21-$0.21
Q2 20241-$0.22-$0.22-$0.22
Q3 20241-$0.16-$0.16-$0.16
Q4 20241-$0.16-$0.16-$0.16
FY 20244-$0.75-$0.75-$0.75
Q1 20251-$0.16-$0.16-$0.16
Q2 20251-$0.16-$0.16-$0.16
Q3 20251-$0.14-$0.14-$0.14
Q4 20251-$0.13-$0.13-$0.13
FY 20254($0.59)($0.59)($0.59)

Enlivex Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
8/30/2024Q2 2024-$0.22-$0.16+$0.06-$0.16--
6/14/2024Q1 2024-$0.25-$0.22+$0.03-$0.22--
3/29/2024Q4 2023--$0.48 -$0.48-$0.48--
11/9/2023Q3 2023-$0.32-$0.32--$0.32--
9/1/2023Q2 2023-$0.43-$0.37+$0.06-$0.37--
6/26/2023Q1 2023-$0.40-$0.40----
6/16/2023Q1 2023-$0.40-$0.39+$0.01-$0.39--
3/31/2023Q4 2022--$0.39 -$0.39-$0.39--
12/5/2022Q3 2022-$0.29-$0.31 -$0.02-$0.31--

Enlivex Therapeutics Earnings - Frequently Asked Questions

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earning data on Friday, August 30, 2024. Learn more on ENLV's earnings history.

In the previous quarter, Enlivex Therapeutics (NASDAQ:ENLV) reported ($0.16) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.22) by $0.06. Learn more on analysts' earnings estimate vs. ENLV's actual earnings.

Enlivex Therapeutics (NASDAQ:ENLV) has a recorded net income of -$29.07 million. ENLV has generated -$1.18 earnings per share over the last four quarters.

Enlivex Therapeutics's earnings are expected to grow from ($0.70) per share to ($0.58) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:ENLV) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners